Antiasthmatic effect of YM976, a novel PDE4 inhibitor, in guinea pigs.
YM976 is a novel and specific phosphodiesterase 4 inhibitor. In our previous report, we indicated that YM976 has less emetogenicity, a major adverse effect of PDE4 inhibitors, than rolipram. In the present study, we examined the antiasthmatic effects of YM976 in guinea pigs. YM976 orally administered exhibited inhibition of antigen-induced bronchoconstriction, airway plasma leakage, airway eosinophil infiltration, and airway hyperreactivity (AHR), with ED(50) values of 7.3, 5.7, 1.0, and 0.52 mg/kg, respectively. Rolipram also dose dependently suppressed these responses. Prednisolone suppressed eosinophil infiltration and AHR, whereas it failed to inhibit bronchoconstriction and plasma leakage. Theophylline moderately suppressed bronchoconstriction and edema, but neither eosinophil infiltration nor AHR. YM976 suppressed the peroxidase activity in the bronchoalveolar lavage fluid, and elevated the intracellular peroxidase activity and cAMP contents of infiltrated cells, suggesting that YM976 inhibited not only the infiltration but also the activation of leukocytes. In vitro studies revealed that YM976 potently suppressed eosinophil activation (EC(30) = 83 nM), and exerted a little relaxation on LTD(4)-precontracted tracheal smooth muscle (EC(50) = 370 nM). Rolipram exhibited a potent tracheal relaxation activity (EC(50) = 50 nM). In vivo studies indicated that the inhibitory effect of YM976 on LTD(4)-induced bronchospasm was marginal even at 30 mg/kg p.o., although rolipram significantly inhibited the bronchospasm at the same dose. These results suggested that YM976, unlike rolipram, showed the inhibition of antigen-induced airway responses due to anti-inflammatory effects, but not to direct tracheal relaxation. In conclusion, YM976 may have potential therapeutic value in the treatment of asthma through its anti-inflammatory activities.
Aoki
M
M
Inflammation Research Pharmacology Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba-shi, Ibaraki, Japan. aokim@yamanouchi.co.jp
Yamamoto
S
S
Kobayashi
M
M
Ohga
K
K
Kanoh
H
H
Miyata
K
K
Honda
K
K
Yamada
T
T
D000818:Animals; D018927:Anti-Asthmatic Agents / Q000494:pharmacology*; D016535:Bronchial Hyperreactivity / Q000517:prevention & control; D001986:Bronchial Spasm / Q000517:prevention & control; D016084:Bronchoconstriction / Q000187:drug effects; D004804:Eosinophils / Q000378:metabolism; D006168:Guinea Pigs; D066298:In Vitro Techniques; D017998:Leukotriene D4 / Q000494:pharmacology; D008168:Lung / Q000187:drug effects; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D011744:Pyrimidinones / Q000494:pharmacology*; D013481:Superoxides / Q000378:metabolism
D018927:Anti-Asthmatic Agents; D010726:Phosphodiesterase Inhibitors; D011725:Pyridines; D011744:Pyrimidinones; C414544:YM 976; D013481:Superoxides; D017998:Leukotriene D4